2025 Interim Results 29 July 2025 Delivering income and value growth Successful first half of the year Strong financial performance and enhanced flexibility Delivering income and value growth Confidence in our prospects 2025 Interim Results 2 Successful first half of the Significant growth potential across our portfolio year Option 1 Strong operating and financial performance Growth in earnings, dividends, valuation and NTA Introduction of long-term, private capital Confidence in London's West End – Well-po ...

DataEye研究院观察到，最近一段时间的买量榜单呈现出一种有趣的现象： 中重度游戏素材投放榜TOP50中，72%是小游戏；传奇在微信小游戏再度崛起；TOP10以内的投放量等同于TOP11-50产品投放量的总额... 基于上述内容以及结合DataEye-ADX数据，DataEye研究院投放榜TOP50的产品进行详细剖析。 一、中重度游戏素材投放榜总体情况 【事实&数据】 根据DataEye-ADX中重度游戏素材投放榜显示，7天榜单TOP50产品中（以7月24日为时间点），其中60%是小游戏产品。时间拉长到90天，小游戏占比则 提升至72%。（TOP50图片较长，详情可以点击ADX查看） | 国内版 | | | 首页 游戏素材 √ 小游戏排行榜 ▽ … | | (NEW) | | | | 支持按产品名、媒体、公司、文案搜索 | | Q 国内行业版 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 高级筛选: | | 按天 V | 7天 | V | 产品类型 | V. | 手机平台 | N | (NEW) 信 ...

China’s proposed coal mine developments risk creating an oversupply and derailing climate goals, according to Global Energy Monitor https://t.co/OKW7kIwMWY ...

Exelixis (EXEL) Q2 2025 Earnings Call July 28, 2025 05:00 PM ET Speaker0Day, ladies and gentlemen, and welcome to the Exelixis Second Quarter twenty twenty five Financial Results Conference Call. My name is Towanda, and I'll be your operator for today. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to your host for today, Ms. Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations.Please proceed.Speaker1Thank you, Twanda, and t ...

Exelixis (EXEL -2.65%), an oncology-focused biotech, reported results for Q2 2025 on July 28, 2025. For the period, the company delivered non-GAAP earnings per share (EPS) of $0.75 in Q2 FY2025, beating analyst consensus of $0.66. Revenue totaled $568.3 million, GAAP revenue of $568.3 million was below the analyst estimate of $580.05 million, and Revenue declined 10.8% year-over-year. This shortfall was mainly due to the absence of a $150.0 million milestone recorded in Q2 2024. Solid growth in net product ...

GeoVax Labs (GOVX) Q2 2025 Earnings Call July 28, 2025 04:30 PM ET Company ParticipantsDavid Dodd - Chairman, President & CEOMark Reynolds - CFOJohn W. Sharkey - VP - Business DevelopmentKelly McKee - Chief Medical OfficerJames Molloy - MD & Equity Research - Biotechnology and Specialty PharmaceuticalsConference Call ParticipantsJonathan Aschoff - MD & Senior Research AnalystRobert Leboyer - Senior Biotechnology AnalystJohn Vandermosten - Senior AnalystOperatorGood afternoon, and welcome, everyone, to the G ...

CARLSBAD, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) received two different communications from the staff of the Nasdaq Listing Qualifications office of the Nasdaq Stock Market, LLC. The Company received the first notice from the Nasdaq Listings Qualifications office of the Nasdaq Stock Market LLC on July 23, 2025, informing the Company that as reflected in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed with th ...

Figure 10 AC collar locations over regional geological interpretation and airborne magnetics, showing maximum downhole gold values. Figure 11 Sherlock Crossing, showing extended soil anomaly > 15 ppm Sb to the SW of the proposed first pass drilling area at the Clarke Mine. Share Registry Share Registry Novo Exploration Map Novo Exploration Map Novo completed its maiden RC drill program at the Clone prospect as part of the Tibooburra Gold Project in May 2025 testing 500 m of strike. Drilling ...

CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host a conference call and webcast on Tuesday, July 29, 2025 beginning at 8:00 a.m. ET to present topline results from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. Members of Fulcrum management will be j ...

[Music] So I am here to talk about how building products is really about shipping something to someone always wins and that's kind of been been a fundamental product principle of mine. Um really short background I know the sign out there says say Microsoft that's a long time ago I was at Microsoft but I was at Microsoft as part of the early VS code team building that left in 19 we became the market leader spend some time at Stripe running our developer platform or building a big part of our developer platfo ...